CERE Stock Overview
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases.
Cerevel Therapeutics Holdings, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$28.37|
|52 Week High||US$41.46|
|52 Week Low||US$19.86|
|1 Month Change||-3.24%|
|3 Month Change||-3.96%|
|1 Year Change||-13.59%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||138.40%|
Recent News & Updates
|CERE||US Biotechs||US Market|
Return vs Industry: CERE underperformed the US Biotechs industry which returned -10.2% over the past year.
Return vs Market: CERE exceeded the US Market which returned -14.8% over the past year.
|CERE Average Weekly Movement||7.5%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: CERE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CERE's weekly volatility (7%) has been stable over the past year.
About the Company
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company’s products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson’s disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder.
Cerevel Therapeutics Holdings, Inc. Fundamentals Summary
|CERE fundamental statistics|
Is CERE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CERE income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.03|
|Net Profit Margin||0.00%|
How did CERE perform over the long term?See historical performance and comparison